Clinical Trial Update: Rotavirus Efficacy and Safety Trial (REST)(V260-006) [Phase 3]

View source ↗

Summary

Phase 3 Rotavirus Efficacy and Safety Trial REST (V260-006) completed with efficacy and safety results posted in 2011. The trial evaluated Merck's rotavirus vac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rotavirus Infections

Drugs mentioned

• RotaTeq (Rotavirus vaccine, live, pentavalent) (Rotavirus vaccine, live, pentavalent)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Rotavirus Infections | Phase 3 | Status: COMPLETED | Results posted: 2011-05-05